Celldex Therapeutics Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, Celldex Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $57.53. The average 1-year stock price forecast is 63.16% higher than the current stock price, while the lowest is $38 (+7.77%) and the highest is $90 (+155.25%).

Price Target: $57.53 (+63.16%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$38	$57.53	$54	$90
Change	+7.77%	+63.16%	+53.15%	+155.25%

Analyst Ratings

The average analyst rating for Celldex Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	12	12	13	12	12	13
Buy	1	1	1	2	2	2
Hold	2	2	1	1	1	1
Sell	1	1	1	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	16	16	15	15	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $42	Buy	Reiterates	$42	+19.12%	Jun 15, 2026
Andy Chen Wolfe Research	Wolfe Research	Buy Maintains $51 → $44	Buy	Maintains	$51 → $44	+24.79%	Jun 15, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Maintains $44	Buy	Maintains	$44	+24.79%	Jun 12, 2026
David Dai UBS	UBS	Buy Maintains $38 → $45	Buy	Maintains	$38 → $45	+27.62%	Jun 10, 2026
Derek Archila Wells Fargo	Wells Fargo	Buy Reiterates $38 → $54	Buy	Reiterates	$38 → $54	+53.15%	May 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

2.63M

from 1.55M

70.53%

from 1.55M

Revenue Next Year

11.96M

from 2.63M

354.03%

from 2.63M

EPS This Year

-4.39

from -3.90

EPS Next Year

-4.50

from -4.39

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	4.65M	2.36M	6.88M	7.02M	1.55M	2.63M
Revenue Growth	-37.30%	-49.32%	192.02%	1.99%	-77.99%	70.53%
Gross Profit	-48.66M	-79.90M	-111.13M	-156.53M	-243.53M	2.63M
Gross Margin	-1,046.23%	-3,389.94%	-1,614.53%	-2,229.77%	-15,762.39%	100.00%
Operating Income	-69.15M	-107.10M	-142.04M	-195.08M	-287.37M	-345.67M
Net Income	-70.51M	-112.33M	-141.43M	-157.86M	-258.76M	-330.06M
EPS	-	-	-	-	-3.90	-4.39
Free Cash Flow	-29.71M	-58.03M	-46.70M	-91.67M	-125.54M	-280.67M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	9.0M
Avg	2.6M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	482.5%
Avg	70.5%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-4.03
Avg	-4.39
Low	-4.57

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-